Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382438 | 0.83 | MLLT1 (0.58) | MLLT1LIPGSMN1; SMN2LMNA | |
| SCHEMBL6255257 | 0.81 | SMN1; SMN2 (0.44) | LIPGSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL17093844 | 0.80 | CYP24A1 (0.33) | MEN1KMT2AL3MBTL1TBXAS1ALDH1A1 | |
| SCHEMBL10048209 | 0.79 | KMT2A (0.50) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL23455649 | 0.79 | SMN1; SMN2 (0.54) | LIPGSMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL4615564 | 0.78 | NAMPT (0.51) | L3MBTL1CYP19A1 | |
| SCHEMBL24000994 | 0.78 | NAMPT (0.47) | SMN1; SMN2HTTL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL19851470 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL31737685 | 0.77 | CYP11B1 (0.46) | SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL17094178 | 0.77 | L3MBTL1 (0.36) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482487-B2 | Phenylaminoethanol derivatives as β2 receptor agonists | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | BROWN ALAN D | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | ADRB2, ADRB1, ADRA2C | MLLT1 1460/4885LIPG 2986/4885SMN1; SMN2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.